Recently, a study on patients affected by neurogenerative diseases has evidenced altered levels of GFAP and TREM-2 in CSF, suggesting that they could be used as biomarkers of central inflammation and have been proposed as prognostic tools of neurodegenerative progression [56]. This evidence concerns the gene GFAP and glycogen storage disease VI.